Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis
Abstract Background Immunotherapy or apatinib alone has been used as third-line adjuvant therapy for advanced or metastatic gastric/gastroesophageal junction (G/GEJ) tumors, but the efficacy of combining them with each other for the treatment of patients with advanced or metastatic G/GEJ is unknown;...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2024-05-01
|
| シリーズ: | BMC Cancer |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12885-024-12340-4 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|